Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Involved in the costimulatory signal essential for T- cell proliferation and IFNG production in a PDCD1-independent manner. Additionally we are shipping PD-L1 Proteins (83) and PD-L1 Kits (53) and many more products for this protein.
Showing 10 out of 365 products:
Mouse (Murine) Polyclonal PD-L1 Primary Antibody for CyTOF, FACS - ABIN4899388
Wang, Yoshida, Nakaki, Hiai, Okazaki, Honjo: Establishment of NOD-Pdcd1-/- mice as an efficient animal model of type I diabetes. in Proceedings of the National Academy of Sciences of the United States of America 2005
Show all 7 Pubmed References
Human Monoclonal PD-L1 Primary Antibody for FACS, IHC (p) - ABIN1449244
Mandavilli: Hormone in the hot seat. in Nature medicine 2006
Show all 8 Pubmed References
Human Polyclonal PD-L1 Primary Antibody for ELISA, FACS - ABIN4282770
Aguilar, Shirley, Chung, Marsh, Walker, Coyle, Marx, Bekaii-Saab, Lesinski, Swanson, Sanchez, Manzanera, Aguilar-Cordova, Bloomston: Gene-mediated cytotoxic immunotherapy as adjuvant to surgery or chemoradiation for pancreatic adenocarcinoma. in Cancer immunology, immunotherapy : CII 2015
Show all 2 Pubmed References
Human Polyclonal PD-L1 Primary Antibody for IHC, ELISA - ABIN1002984
Holling, Schooten, van Den Elsen: Function and regulation of MHC class II molecules in T-lymphocytes: of mice and men. in Human immunology 2004
Show all 3 Pubmed References
Human Monoclonal PD-L1 Primary Antibody for IHC (p), ELISA - ABIN1995635
Soliman, Khalil, Antonia: PD-L1 expression is increased in a subset of basal type breast cancer cells. in PLoS ONE 2014
Show all 2 Pubmed References
Human Polyclonal PD-L1 Primary Antibody for IHC (p), WB - ABIN2479616
Ishida, Agata, Shibahara, Honjo: Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. in The EMBO journal 1992
Show all 3 Pubmed References
Human Polyclonal PD-L1 Primary Antibody for IHC, ELISA - ABIN1031034
Angell, Lechner, Jang, Correa, LoPresti, Epstein: BRAF(V600E) in Papillary Thyroid Carcinoma is Associated with Increased Programmed Death Ligand 1 Expression and Suppressive Immune Cell Infiltration. in Thyroid : official journal of the American Thyroid Association 2014
Human Monoclonal PD-L1 Primary Antibody for FACS - ABIN4896033
Nicolazzo, Raimondi, Mancini, Caponnetto, Gradilone, Gandini, Mastromartino, Del Bene, Prete, Longo, Cortesi, Gazzaniga: Monitoring PD-L1 positive circulating tumor cells in non-small cell lung cancer patients treated with the PD-1 inhibitor Nivolumab. in Scientific reports 2016
Human Monoclonal PD-L1 Primary Antibody for CyTOF, FACS - ABIN4899390
Rojas, Krishnan: IFN-gamma generates maturation-arrested dendritic cells that induce T cell hyporesponsiveness independent of Foxp3+ T-regulatory cell generation. in Immunology letters 2010
B7-H1 induction in keratinocytes may play a crucial role in the protection from CD4 (show CD4 Antibodies)+ T cell-mediated tissue inflammation by exogenous antigens delivered from the mucosal surface in oral cavity
Interferon (show IFNA Antibodies)-related secretome from direct interaction between immune cells and tumor cells is required for upregulation of PD-L1 in tumor cells.
RAS signaling can upregulate tumor cell PD-L1 expression through a mechanism involving increases in PD-L1 mRNA stability via modulation of the AU-rich element-binding protein tristetraprolin (show ZFP36 Antibodies).
Data (including data from studies in transgenic/knockout mice) suggest that T-cell expression of Mirn155 is required to limit melanoma growth; miR (show MLXIP Antibodies)-155, Pdcd1 (show PDCD1 Antibodies), Pdcd1l1, and Ctla4 (show CTLA4 Antibodies) appear to regulate overlapping pathways promoting antitumor immunity. [Mirn155 = microRNA 155; Pdcd1 (show PDCD1 Antibodies) = programmed cell death 1 (show PDCD1 Antibodies) protein; Pdcd1l1 = programmed cell death 1 ligand 1 protein; Ctla4 (show CTLA4 Antibodies) = cytotoxic T-lymphocyte-associated protein 4 (show CTLA4 Antibodies)]
Expression of LAP/TGF-beta1 (show TGFB1 Antibodies), CD80 (show CD80 Antibodies), CD86 (show CD86 Antibodies) and PD-L1 is significantly increased in tumor-infiltrating B cells (TIL (show TLR1 Antibodies)-B) relative to splenic B cells. LAP/TGF-beta1 (show TGFB1 Antibodies) expression on TIL (show TLR1 Antibodies)-B progressively increased from 5.4+/-1.7% on day 8 to 43.1+/-6.1% by day 21 post tumor implantation.
spleen-derived IFN-gamma (show IFNG Antibodies) induces generation of PD-L1(+)-suppressive neutrophils.
PD-L1 and PD-L2 (show PDCD1LG2 Antibodies) in dermal fibroblasts is up-regulated by activated T cells in alopecia areata-affected skin.
It was concluded that down-regulated expression of miR (show MLXIP Antibodies)-143 and up-regulation of its direct target B7H1 may indicate a novel therapeutic method for radiation-induced thymic lymphoma by increased expression of miR (show MLXIP Antibodies)-143 or inhibition of B7H1.
HDAC6 (show HDAC6 Antibodies) inhibition reduces tumor growth and PD-L1 production in vivo.
findings indicate that the PerC (show PPARGC1B Antibodies) B cells, including PD-L1/PD-L2 (show PDCD1LG2 Antibodies) B-1a cells, may suppress T cells responding to allostimulation, and thus may be optimal for donor lymphocyte injection
The presence of PD-L1 expression in association with immune-infiltrating cells and HLA class I (show MICA Antibodies) expression in nearly 50% of the dedifferentiated chondrosarcomas provides rationale for including these patients in clinical trials with PD-1 (show PDCD1 Antibodies)/PD-L1-targeted therapies.
Paired Comparison of PD-L1 Expression on Cytologic and Histologic Specimens From Malignancies in the Lung Assessed With PD-L1 IHC 28-8pharmDx and PD-L1 IHC 22C3pharmDx.
PD-L1 was found variably expressed in the cytoplasm and the cell surface of both HO8910 and SKOV3 cells. TAM (show CCNA1 Antibodies) or IFN-gamma (show IFNG Antibodies), TNF-alpha (show TNF Antibodies), IL-10 (show IL10 Antibodies) and IL-6 (show IL6 Antibodies) released from TAM (show CCNA1 Antibodies) stimulated the expression of PD-L1 at the surface of the cancer cells. The IHC results were consistent with the data in vitro showing infiltration of TAM (show CCNA1 Antibodies) correlated with membranous PD-L1.
Results showed that PD-L1 expression on solid tumor cells was upregulated by IFNG (show IFNG Antibodies) mainly through JAK (show JAK3 Antibodies)-STAT (show STAT1 Antibodies) pathway and membranous PD-L1 expression on tumor cells in the tumor microenvironment of gastric cancer was significantly positively correlated with tumor stroma CD8 (show CD8A Antibodies)-positive T cells and tumor IFNG (show IFNG Antibodies) levels.
PD-L1 expression in provides normally immunogenic colorectal carcinoma a means of immune evasion and a more aggressive biology.
Data suggest that TNFalpha (show TNF Antibodies) and IFNgamma synergistically induce PDL1 expression in dermal lymphatic endothelial cells; in this process, expression of microRNA-155 is up-regulated; PDL1 3prime-untranslated region contains two functional microRNA-155 binding sites/response elements. (PDL1 = programmed death ligand-1 protein; IFNgamma = interferon-gamma (show IFNG Antibodies); TNFalpha (show TNF Antibodies) = tumor necrosis factor-alpha (show TNF Antibodies))
Data suggest that hormonal 1,25-dihydroxyvitamin D is a direct transcriptional inducer of genes encoding PDL1 and PDL2 (show PDCD1LG2 Antibodies) in myeloid cells/macrophages; this up-regulation of gene expression appears to be species- and cells-specific.
CMTM6 (show CMTM6 Antibodies) is present at the cell surface, associates with the PD-L1 protein, reduces its ubiquitination and increases PD-L1 protein half-life; CMTM6 (show CMTM6 Antibodies) enhances the ability of PD-L1-expressing tumour cells to inhibit T cells; collectively, our data reveal that PD-L1 relies on CMTM6 (show CMTM6 Antibodies)/4 to efficiently carry out its inhibitory function, and suggest potential new avenues to block this pathway
CMTM6 (show CMTM6 Antibodies) depletion, via the reduction of PD-L1, significantly alleviates the suppression of tumour-specific T cell activity in vitro and in vivo; findings provide insights into the biology of PD-L1 regulation, identify a previously unrecognized master regulator of this critical immune checkpoint and highlight a potential therapeutic target to overcome immune evasion by tumour cells
PD-L1 underexpression is associated with gastric cancer.
These results suggest that the soluble recombinant proteins may be used to prepare monoclonal antibodies to block the PD-1 (show PDCD1 Antibodies)/PD-L1 pathway.
role of programmed death ligand-1 (PD-L1) during porcine circovirus type 2 (PCV2) infection and porcine circovirus associated diseases (PCVAD) development
These data suggest that overexpression of PD-L1 and PD-L2 (show PDCD1LG2 Antibodies) mRNA is one mechanism by which immunosupression of postweaning multisystemic wasting syndrome pigs occurs.
Retinal PLD1 expression is enhanced in radial fibers of Muller cells with age. This finding suggests that PLD1 plays an important role in signal transduction of glial cells and neuronal cells in the retina.
A porcine PD-L1 molecule was cloned using RACE (rapid amplification of cDNA ends) technology and sequenced (GenBank # AY837780); it showed high sequence homology with human PD-L1.
This study provides novel information for the understanding of signalling through PD-L1.
Involved in the costimulatory signal essential for T- cell proliferation and IFNG production in a PDCD1-independent manner. Interaction with PDCD1 inhibits T-cell proliferation by blocking cell cycle progression and cytokine production.
, CD274 antigen
, programmed cell death 1 ligand 1
, programmed cell death ligand 1
, B7 homolog 1
, PDCD1 ligand 1
, programmed death ligand 1